Search
Selected Filter
Filter Results
Displaying 181–190 of 199 research results for “stem-cells”
-
Oct 29, 2019
Iveric Bio’s Therapy Slows Retinal Degeneration in Phase 2b Trial for Dry AMD
Zimura inhibits a complement protein known as C5, a component of the immune system that, when overactive, can cause retinal degeneration.
-
May 6, 2019
ARVO 2019: Gene Therapy Clinical Trial for RP Caused by RLBP1 Mutations Ongoing in Sweden
In a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
-
May 3, 2019
ARVO 2019: Robot-Assisted Surgery in Clinical Trial for Retinal Disease
A video from a clinical trial of robot-assisted surgery demonstrates the potential benefits of robot-assisted subretinal injections.
-
Apr 30, 2019
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Unlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.
-
Dec 7, 2018
FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10
Editas Medicine, a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth.
-
Dec 4, 2018
ProQR Receives FDA Authorization to Launch Clinical Trial for USH2A Therapy
ProQR, a biotech in the Netherlands developing therapies for rare diseases, has received authorization from the US Food and Drug Administration to launch a Phase I/II clinical trial for QR-421a, its treatment targeting mutations in exon 13 of the USH2A gene.
-
May 30, 2018
French Gene Therapy Company Advancing Three Programs for Retinal Diseases
Horama’s gene therapies are injections of healthy copies of a gene underneath the retina to compensate for the defective gene.
-
Feb 14, 2018
FFB-CRI Investing $7.5 Million in Emerging Therapy for USH2A
The Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has entered into a partnership with ProQR to develop a retinal therapy for people with Usher syndrome type 2A (USH2A) caused by mutations in exon 13 of the USH2A gene.
-
Feb 7, 2018
AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S.
Taking place at five locations in the United States, the clinical trial will enroll approximately 15 males with X-linked retinitis pigmentosa caused by mutations in the gene RPGR and will primarily evaluate safety.
-
Jan 23, 2018
Ophthotech Launching Human Study of Emerging Therapy for Stargardt Disease
Ophthotech, a biopharmaceutical company developing therapies for eye diseases, has enrolled the first patient in its Phase 2b clinical trial of Zimura® for people with Stargardt disease caused by mutations in the gene ABCA4.